• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation - Cervarix, Sept. 18, 2009

System Info - 105687  SHONE, DEANNA   23-Sep-2009 15:50:53  SHONEDE

RECORD OF TELEPHONE CONVERSATION

Submission Type: Original Application   Submission ID:  125259/0    Office: OVRR  

Product:

Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant

Applicant:                                                                       

GlaxoSmithKline Biologicals          

Telecon Date/Time:  18-SEP-2009 12:00 AM                Initiated by FDA?  Yes

Telephone Number:    

Communication Categorie(s):

Advice

Author:  LORI AUSTIN-HANSBERRY

Telecon Summary:

Telecon with OBE/GSK

FDA Participants:  

Non-FDA Participants:   

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:


 

Subject: Notes from GSK Meeting (Telecon) on September 18, 2009

Participants:

FDA

Dr. Rickey Wilson

Dr. Hector Izurieta

Dr. Michael Nguyen

GSK

Dr. Clare Kahn (GSK

GSK contacted FDA on September 18 to clarify the terms of the postmarketing study requirement. GSK was concerned about committing to absolute study metrics that might later turn out not to be feasible once the study is initiated.

In particular, they were concerned that in their preliminary sample size calculations, GSK estimated that approximately 500,000 women would need to be monitored to achieve sufficient power to detect a relative risk of 2.0 for spontaneous abortions. Hence, GSK asked that the vaccine approval letter only include a broad outline of the study protocol, with the understanding that (a) GSK was fully committed to a post licensure study to assess the risk of spontaneous abortions after Cervarix vaccination and (b) FDA must approve the final study design.

The terms agreed upon were that the approval letter would state the following:

(1) Full commitment to a postmarketing analytic epidemiologic study

(2) Study population would be women whose estimated date of conception occurred -30 to +90 days of nearest vaccination.

(3) The study would include karyotype analysis in a subset of women.

(4) The draft protocol would be submitted 2 months after product licensure and the final protocol 6 months after product licensure.

(5) The study would commence preferably within 6 months but no longer than 12 months after study protocol finalization.

Michael D. Nguyen, MD

LCDR, U.S. Public Health Service

Medical Officer | Vaccine Safety Branch

301-827-2952

FDA | Center for Biologics Evaluation and Research

Woodmont Office Complex 1, Rm 473S, HFM-222

1401 Rockville Pike, Suite 400S

Rockville, MD 20852